Skip to content

Study · Randomized controlled trial · n = 42 · 1985

4 results

A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.

Schulof RS, Lloyd MJ, Cleary PA, Palaszynski SR, Mai DA, Cox JW Jr, Alabaster O, Goldstein AL

Journal of biological response modifiers1 Apr 1985Cited by 36 (Europe PMC)

PMID3998766 (opens in a new tab)PepBankPUB-03998766
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postradiotherapy patients with non-small cell lung cancer, thymosin treatment was associated with significant improvement in relapse-free survival, most pronounced for nonbulky tumors.

    In plain wordsIn people with lung cancer after radiotherapy, thymosin treatment was linked to longer time without relapse, most clearly in people with nonbulky tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseRelapse-free survival
    Study

    n = 42

    Comparator
    Placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin treatment was associated with significant improvements in relapse-free and overall survival, which was most pronounced for patients with nonbulky tumors.
    1 context sentence
    Summary · context
    A randomized trial was performed in 42 postradiotherapy patients with non-small cell lung cancer to determine whether the administration of synthetic thymosin-alpha 1 by either a loading dose or a twice-weekly schedule could accelerate the reconstitution of thymic dependent immunity.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postradiotherapy patients with non-small cell lung cancer, thymosin treatment was associated with significant improvement in overall survival, most pronounced for nonbulky tumors.

    In plain wordsIn people with lung cancer after radiotherapy, thymosin treatment was linked to longer overall survival, most clearly in people with nonbulky tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOverall survival
    Study

    n = 42

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin treatment was associated with significant improvements in relapse-free and overall survival, which was most pronounced for patients with nonbulky tumors.
    1 context sentence
    Summary · context
    A randomized trial was performed in 42 postradiotherapy patients with non-small cell lung cancer to determine whether the administration of synthetic thymosin-alpha 1 by either a loading dose or a twice-weekly schedule could accelerate the reconstitution of thymic dependent immunity.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postradiotherapy patients with non-small cell lung cancer, a loading dose of thymosin alpha‑1 normalized T cell function (p = 0.04) while placebo patients showed no improvement.

    In plain wordsIn people with lung cancer after radiotherapy, a loading dose of thymosin alpha‑1 normalized T cell function, while placebo did not improve it.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseT cell function, loading dose regimen
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients treated with thymosin by the loading dose regimen exhibited a normalization of T cell function (p = 0.04), whereas patients treated with the twice-weekly schedule maintained normal helper T cell percentages (p = 0.04).
    2 context sentences
    Summary · context
    Placebo-treated patients did not show any improvement in T cell numbers or function over 15 weeks of serial immune monitoring, and exhibited gradual depressions of helper T lymphocyte percentages.
    Summary · context
    A randomized trial was performed in 42 postradiotherapy patients with non-small cell lung cancer to determine whether the administration of synthetic thymosin-alpha 1 by either a loading dose or a twice-weekly schedule could accelerate the reconstitution of thymic dependent immunity.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postradiotherapy patients with non-small cell lung cancer, a twice-weekly schedule of thymosin alpha‑1 maintained normal helper T cell percentages (p = 0.04), while placebo patients showed gradual depressions.

    In plain wordsIn people with lung cancer after radiotherapy, twice-weekly thymosin alpha‑1 kept helper T cell percentages normal, while they fell gradually with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHelper T cell percentage, twice-weekly schedule
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients treated with thymosin by the loading dose regimen exhibited a normalization of T cell function (p = 0.04), whereas patients treated with the twice-weekly schedule maintained normal helper T cell percentages (p = 0.04).
    2 context sentences
    Summary · context
    Placebo-treated patients did not show any improvement in T cell numbers or function over 15 weeks of serial immune monitoring, and exhibited gradual depressions of helper T lymphocyte percentages.
    Summary · context
    A randomized trial was performed in 42 postradiotherapy patients with non-small cell lung cancer to determine whether the administration of synthetic thymosin-alpha 1 by either a loading dose or a twice-weekly schedule could accelerate the reconstitution of thymic dependent immunity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT05790447

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow Universityn = 60est. 1 Apr 2023 to est. Dec 2025

Advanced Solid Tumor · Refractory Tumor

Trial pageClinicalTrials.govUpdated 30 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.